Affibody AB
556665-6913ActiveDeveloping next-generation radiopharmaceuticals using proprietary Affibody technology.
Oversigt
- 50–99
- Medarbejdere
- 20–50mio SEK
- Omsætning
- 2004
- Grundlagt
Nøglebeslutningstagere
Peter Zerhouni
Chief Financial Officer and Chief Business Officer
David Bejker
President and Chief Executive Officer
Mathias Uhlén
Board Director
Anders Martin-Löf
Board Director
+11 flere kontakter i Funnelfeedr
Beskrivelse
Affibody is a specialized biotechnology company focused on creating next-generation radiopharmaceuticals. They leverage their proprietary Affibody® platform to develop radioligand therapeutics (RLTs) designed for precision targeting. The company strategically focuses its pipeline on major cancer typ...
Tags
Nøgleord
Teknologistak
Virksomhedsoplysninger
- Branche
- Bioteknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- Momsnummer
- SE556665691301
Beslutningstagere
15 kontakter i FunnelfeedrPeter Zerhouni
Chief Financial Officer and Chief Business Officer
David Bejker
President and Chief Executive Officer
Mathias Uhlén
Board Director
Anders Martin-Löf
Board Director
Jakob Lindberg
Board Director
Guido Wuerth
Head Corporate Development, Radiopharma
Karin Nord
Senior Vice President Research Operations
Fredrik Frejd
Chief Scientific Officer
Rachel Humphrey
Board Director
Robert Burns
Chair of the Board
Michael Monaghan
Board Director (Employee Representative)
Rezan Güler
Board Director (Employee Representative)
Filippa Stenberg
Board Director
Gillian M Cannon
Board Director
Jonathan Knowles
Board Director
Lignende virksomheder
20 lignende virksomheder i FunnelfeedrAffibody Medical AB
Developing next-generation radiopharmaceuticals using proprietary Affibody platform.
AAX Biotech AB
5–9 medarbejdereResearch-driven biotech advancing antibody therapies via proprietary technology.
ZEALAND PHARMA A/S
0 medarbejdereDeveloping peptide medicines for metabolic health challenges globally.
Oblique Therapeutics AB (publ)
10–19 medarbejdereInnovative biotech developing breakthrough antibodies using the AbiProt platform.
Oncopeptides AB
20–49 medarbejdereDeveloping targeted cancer therapies for difficult-to-treat diseases.
Udforsk mere
Spørgsmål om Affibody AB
Vil du se Funnelfeedr i aktion?
Book en gratis demo og opdag, hvordan Funnelfeedr hjælper dig med at finde og konvertere dine ideelle kunder.
Book en demo